author-photo

Haofei Tiffany Wang

Ipsen

4

Papers

3

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)